WO2003096965A3 - Derives de quinoleine a effet anti-integrase et leurs applications comme antiviraux - Google Patents

Derives de quinoleine a effet anti-integrase et leurs applications comme antiviraux Download PDF

Info

Publication number
WO2003096965A3
WO2003096965A3 PCT/FR2003/001487 FR0301487W WO03096965A3 WO 2003096965 A3 WO2003096965 A3 WO 2003096965A3 FR 0301487 W FR0301487 W FR 0301487W WO 03096965 A3 WO03096965 A3 WO 03096965A3
Authority
WO
WIPO (PCT)
Prior art keywords
applications
quinoline derivatives
integrase
medicines
effect
Prior art date
Application number
PCT/FR2003/001487
Other languages
English (en)
Other versions
WO2003096965A2 (fr
Inventor
Aurelie Mousnier
Catherine Dargemont
Sabine Bonnenfant
Herve Leh
Jean-Francois Mouscadet
Fatima Zouhiri
Angelo Jean D
Didier Desmaele
Original Assignee
Bioalliance Pharma Sa
Aurelie Mousnier
Catherine Dargemont
Sabine Bonnenfant
Herve Leh
Jean-Francois Mouscadet
Fatima Zouhiri
Angelo Jean D
Didier Desmaele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma Sa, Aurelie Mousnier, Catherine Dargemont, Sabine Bonnenfant, Herve Leh, Jean-Francois Mouscadet, Fatima Zouhiri, Angelo Jean D, Didier Desmaele filed Critical Bioalliance Pharma Sa
Priority to CA002489102A priority Critical patent/CA2489102A1/fr
Priority to EP03752821A priority patent/EP1507532A2/fr
Priority to JP2004504964A priority patent/JP2005531554A/ja
Priority to US10/514,631 priority patent/US7479497B2/en
Priority to IL16526903A priority patent/IL165269A0/xx
Priority to AU2003251047A priority patent/AU2003251047A1/en
Publication of WO2003096965A2 publication Critical patent/WO2003096965A2/fr
Publication of WO2003096965A3 publication Critical patent/WO2003096965A3/fr
Priority to US12/042,628 priority patent/US20080161350A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

L'invention vise l'utilisation de dérivés de l'acide 8-hydroxyquinoléine 7-carboxylique pour fabriquer des médicaments inhibiteurs d'intégrase, capables de bloquer la réplication virale aux étapes précédant l'intégration, et le cas échéant au niveau de cette étape d'intégration, ces médicaments étant utilisables pour le traitement de pathologies rétrovirales, en particulier pour le traitement du Sida.
PCT/FR2003/001487 2002-05-17 2003-05-15 Derives de quinoleine a effet anti-integrase et leurs applications comme antiviraux WO2003096965A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002489102A CA2489102A1 (fr) 2002-05-17 2003-05-15 Derives de quinoleine a effet anti-integrase et leurs applications comme antiviraux
EP03752821A EP1507532A2 (fr) 2002-05-17 2003-05-15 Utilisation de derives de quinoleine a effet anti-integrase et ses applications
JP2004504964A JP2005531554A (ja) 2002-05-17 2003-05-15 抗インテグラーゼ作用をもつキノリン誘導体類の利用およびそれらの応用
US10/514,631 US7479497B2 (en) 2002-05-17 2003-05-15 Use of quinoline derivatives with anti-integrase effect and applications thereof
IL16526903A IL165269A0 (en) 2002-05-17 2003-05-15 Use of quinoline derivatives with anti-integrase effect and applications thereof
AU2003251047A AU2003251047A1 (en) 2002-05-17 2003-05-15 Use of quinoline derivatives with anti-integrase effect and applications thereof
US12/042,628 US20080161350A1 (en) 2002-05-17 2008-03-05 Use of quinoline derivatives with anti-integrase effect and applications thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0206126A FR2839646B1 (fr) 2002-05-17 2002-05-17 Utilisation de derives de quinoleine a effet anti-integrase et ses applications
FR0206126 2002-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/042,628 Division US20080161350A1 (en) 2002-05-17 2008-03-05 Use of quinoline derivatives with anti-integrase effect and applications thereof

Publications (2)

Publication Number Publication Date
WO2003096965A2 WO2003096965A2 (fr) 2003-11-27
WO2003096965A3 true WO2003096965A3 (fr) 2004-04-22

Family

ID=29286592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/001487 WO2003096965A2 (fr) 2002-05-17 2003-05-15 Derives de quinoleine a effet anti-integrase et leurs applications comme antiviraux

Country Status (8)

Country Link
US (2) US7479497B2 (fr)
EP (1) EP1507532A2 (fr)
JP (1) JP2005531554A (fr)
AU (1) AU2003251047A1 (fr)
CA (1) CA2489102A1 (fr)
FR (1) FR2839646B1 (fr)
IL (1) IL165269A0 (fr)
WO (1) WO2003096965A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542352A (ja) * 2005-06-01 2008-11-27 ビオアリアンス ファルマ キノリン化合物及び他のｈｉｖ感染治療薬を含む相乗作用のコンビネーション
SI2220076T1 (sl) * 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
RU2503679C2 (ru) * 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
EA201200631A1 (ru) * 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
WO2009062308A1 (fr) * 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du virus de l'immunodéficience humaine
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
PE20130525A1 (es) * 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
CA2833377C (fr) 2011-04-21 2019-02-12 Gilead Sciences, Inc. Composes benzothiazoles et leur utilisation pharmaceutique
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
PE20141558A1 (es) 2012-04-20 2014-11-06 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761687A1 (fr) * 1997-04-08 1998-10-09 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
WO2003031413A1 (fr) * 2001-10-12 2003-04-17 Bioalliance Pharma Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761687A1 (fr) * 1997-04-08 1998-10-09 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
WO2003031413A1 (fr) * 2001-10-12 2003-04-17 Bioalliance Pharma Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
POLANSKI ET AL.: "USE OF THE KOHONEN NEURAL NETWORK FOR RAPID SCREENING OF EX VIVO ANTI-HIV ACTIVITY OF STYRYLQUINOLINES", J. MED. CHEM., vol. 45, 10 October 2002 (2002-10-10), pages 4647 - 4654, XP002258251 *
ZOUHIRI F ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS AND BINDING MODE OF STYRYLQUINOLINES AS POTENT INHIBITORS OF HIV-1 INTEGRASE AND REPLICATION OF HIV-1 IN CELL CULTURE", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, 2000, pages 1533 - 1540, XP000926747, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
US20080161350A1 (en) 2008-07-03
IL165269A0 (en) 2005-12-18
FR2839646B1 (fr) 2008-04-11
AU2003251047A8 (en) 2003-12-02
US20050261336A1 (en) 2005-11-24
FR2839646A1 (fr) 2003-11-21
JP2005531554A (ja) 2005-10-20
CA2489102A1 (fr) 2003-11-27
EP1507532A2 (fr) 2005-02-23
US7479497B2 (en) 2009-01-20
AU2003251047A1 (en) 2003-12-02
WO2003096965A2 (fr) 2003-11-27

Similar Documents

Publication Publication Date Title
WO2005077050A3 (fr) Inhibiteurs de l'integrase du vih
WO2003096965A3 (fr) Derives de quinoleine a effet anti-integrase et leurs applications comme antiviraux
WO2005115398A3 (fr) Inhibiteurs d'integrase de vih
WO2005102392A3 (fr) Methodes de traitement d'une infection a vih
WO2004055010A3 (fr) Composes de cyclopropyle servant d'antagonistes de ccr5
WO2007019098A3 (fr) Inhibiteurs de l'integrase du vih
WO2002036734A3 (fr) Aza- et polyaza-naphtalenyl cetones utiles en tant qu'inhibiteurs de l'integrase du vih
WO2006034001A3 (fr) Procedes de traitement de l'infection par vih
WO2004054581A3 (fr) Composes de cyclohexyle utiles en tant qu'antagonistes du ccr5
WO2006078287A3 (fr) Inhibiteurs de pde4b
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2000051587A3 (fr) Inhibiteurs de jak-3 destines au traitement de troubles allergiques
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
WO2005076861A3 (fr) Composes inhibant la formation de particule du vih
WO2006034491A3 (fr) Composes a base de quinoleine et de quinazoline a substitution phenylique pour le traitement du diabete
WO2004071382A3 (fr) Heterocycles substitues
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
WO2006054182A3 (fr) Phosphoindoles utilisés en tant qu'inhibiteurs du vih
WO2004050036A3 (fr) Quinoleines et derives nitrogenes de ces composes ainsi que leur utilisation en tant qu'agents antibacteriens
WO2011060534A8 (fr) Mutants trim5alpha et leurs utilisations
WO2004101512A3 (fr) Inihbiteurs de l'integrase de la naphtyridine
WO2004065406A3 (fr) Peptides derives de rantes
WO2007019101A3 (fr) Inhibiteurs de la vih integrase
WO2003045364A3 (fr) Utilisation therapeutique
WO2005063757A3 (fr) Nouvelles formes cristallines de temozolomide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2489102

Country of ref document: CA

Ref document number: 2004504964

Country of ref document: JP

Ref document number: 165269

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003752821

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4013/DELNP/2004

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2003752821

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10514631

Country of ref document: US